$9.28
$8.88
$22.10
$6.79
$1.6B
-45.14%
This is a preview of the full version of Prosperse
The article discusses the rise and fall of Teladoc Health and the potential of Hims & Hers Health, a newer player in the telemedicine industry. It questions whether Hims & Hers can sustain its recent growth and compete with big pharma, drawing parallels to Teladoc's downfall.
Adam Spatacco
Sep 11, 2024
Hims & Hers Health, Inc. (HIMS) has seen a 45.8% stock price increase in the past three months, outperforming the industry and broader market. The company's recent announcements, including the addition of GLP-1 injections to its weight loss portfolio and positive 2024 revenue outlook, have contribut...
Zacks Investment Research
Aug 5, 2024
Teladoc, the telemedicine company, is struggling with negative earnings and declining sales, particularly in its BetterHelp unit. The company's $18.5 billion acquisition of Livongo four years ago continues to weigh on its performance, with a massive noncash asset impairment charge contributing to it...
Rich Smith
Aug 1, 2024
Cathie Wood's ARK ETFs made significant portfolio adjustments, selling Teladoc shares, increasing CrowdStrike holdings, and reducing Tesla positions.
Investing.Com
Jul 23, 2024
Date: Oct 25, 2024
Date: Oct 25, 2024
Date: Oct 25, 2024
Date: Oct 24, 2024
Date: Oct 24, 2024